Your browser doesn't support javascript.
loading
Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome
Pejcic, Ana V; Jankovic, Slobodan M; Davidovic, Goran.
  • Pejcic, Ana V; University of Kragujevac. Faculty of Medical Sciences. Department of Pharmacology and Toxicology. Kragujevac. RS
  • Jankovic, Slobodan M; University of Kragujevac. Faculty of Medical Sciences. Department of Pharmacology and Toxicology. Kragujevac. RS
  • Davidovic, Goran; University of Kragujevac. Faculty of Medical Sciences. Department of Internal Medicine. Kragujevac. RS
Braz. J. Pharm. Sci. (Online) ; 58: e19868, 2022. tab
Article Dans Anglais | LILACS | ID: biblio-1383982
ABSTRACT
Abstract The aim of our study was to assess risk factors for potential drug-drug interactions (pDDIs) of statins across different phases of treatment of acute coronary syndrome (ACS) patients from the point of first medical contact to the coronary angiography (first phase), after coronary angiography to the last day of hospitalization (second phase) and at discharge from hospital (third phase). This was a post hoc analysis of the data collected during the retrospective observational cohort study conducted at the Clinic for Cardiology of the Clinical Centre Kragujevac, Serbia. Patients prescribed statins were identified from the original study population 156, 240 and 236 patients for the first, second and third phases, respectively. At least one statin pDDI was present in 113 (72.4%), 161 (67.1%) and 139 (58.9%) patients in the first, second and third phases, respectively. Heart failure, arrhythmias after ACS, CRP, triglycerides, length of hospitalization, number of prescribed drugs, antiarrhythmic drugs, and clopidogrel seem to increase the risk of statin pDDIs in at least one treatment phase. Physicians should be vigilant to the possibility of statin pDDIs in ACS patients who have factors that may increase their rate.
Sujets)


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Patients / Facteurs de risque / Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase / Interactions médicamenteuses / Syndrome coronarien aigu Type d'étude: Etude d'étiologie / Étude observationnelle / Étude pronostique / Facteurs de risque Limites du sujet: Adulte / Femelle / Humains / Mâle Pays comme sujet: Europe langue: Anglais Texte intégral: Braz. J. Pharm. Sci. (Online) Thème du journal: Farmacologia / Terapˆutica / Toxicologia Année: 2022 Type: Article Pays d'affiliation: Pakistan Institution/Pays d'affiliation: University of Kragujevac/RS

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Patients / Facteurs de risque / Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase / Interactions médicamenteuses / Syndrome coronarien aigu Type d'étude: Etude d'étiologie / Étude observationnelle / Étude pronostique / Facteurs de risque Limites du sujet: Adulte / Femelle / Humains / Mâle Pays comme sujet: Europe langue: Anglais Texte intégral: Braz. J. Pharm. Sci. (Online) Thème du journal: Farmacologia / Terapˆutica / Toxicologia Année: 2022 Type: Article Pays d'affiliation: Pakistan Institution/Pays d'affiliation: University of Kragujevac/RS